Gujarat Themis Biosyn expands into advanced modalities with INR13 billion acquisition of MicroBiopharm Japan
Gujarat Themis Biosyn Limited (GTBL) has agreed to acquire 100% of Japanese CDMO MicroBiopharm Japan (MBJ) from T Capital Partners for INR13 billion. The deal provides GTBL with high-end proprietary platforms in ADC conjugation and plasmid DNA, accelerating its transition into oncology and complex biologics.